Archivel Technologies

Archivel Farma is a Spanish clinical-stage biotechnology company dedicated to developing innovative immunotherapies for infectious and inflammatory diseases. The company's flagship product is RUTI, a polyantigenic therapeutic vaccine currently in Phase 2 clinical trials for the treatment of tuberculosis. RUTI is designed to stimulate a broad immune response against Mycobacterium tuberculosis, particularly targeting latent bacilli that survive standard antibiotic treatments. Archivel Farma operates its own GMP-certified manufacturing facility in Badalona to support its clinical development programs. The company's mission is to improve global health by providing more effective and shorter treatment options for tuberculosis and other complex diseases. Beyond TB, the company is exploring the RUTI platform's potential in indications such as COVID-19 and bladder cancer.